Repeatable and objective method for evaluating angiogenesis using real‐time RT‐PCR of endoglin expression in canine tumours-Reference-Cited by-同舟云学术

Repeatable and objective method for evaluating angiogenesis using real‐time RT‐PCR of endoglin expression in canine tumours

Published:2020-07-26 Issue:1 Volume:19 Page:34-43
ISSN:1476-5810
Container-title:Veterinary and Comparative Oncology
language:en
Short-container-title:Vet Comp Oncol

Author:

Kimura Mayu¹^ORCID,Yamasaki Masahiro¹,Satoh Hiroshi²,Uchida Naohiro¹

Affiliation:

1. Laboratory of Veterinary Small Animal Internal Medicine, Department of Veterinary Medicine, Faculty of Agriculture Iwate University Morioka Japan

2. Laboratory of Veterinary Pharmacology and Toxicology, Department of Veterinary Medicine, Faculty of Agriculture Iwate University Morioka Japan

Publisher

Wiley

Subject

General Veterinary

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vco.12635

Reference41 articles.

1. Tumor Angiogenesis: Therapeutic Implications

2. Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen

3. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

4. Humanization of an anti‐vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders;Presta LG;Cancer Res,1997

5. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression and its relationship to tumor cell proliferation in canine epithelial and mesenchymal tumors;Journal of Veterinary Medical Science;2022

2. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models;BMC Veterinary Research;2021-10-26